1 / 9

Low HDL remains a predictor of cardio - vascular risk in statin-treated patients

Low HDL remains a predictor of cardio - vascular risk in statin-treated patients. Barter P et al., N Engl J Med 2007; 357: 1301-10. dal -VESSEL : Study Design. Dalcetrapib 600 mg. 476 patients randomised. Placebo. Pre- randomisation phase 8 weeks. 4 weeks ABPM.

brianv
Download Presentation

Low HDL remains a predictor of cardio - vascular risk in statin-treated patients

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Low HDL remains a predictorofcardio-vascularrisk in statin-treatedpatients Barter P et al., N Engl J Med 2007; 357: 1301-10

  2. dal-VESSEL: Study Design Dalcetrapib 600 mg 476 patientsrandomised Placebo Pre-randomisation phase8 weeks 4 weeksABPM 12 weeksFMD, ABPM 36 weeksFMD, ABPM RandomisationFMD, ABPM Double-blind randomised, placebo-controlled, parallel-group multicentre FMD/ABPM study in patients with CHD or CHD-risk equivalent

  3. Conclusions from dal-VESSEL • Dalcetrapib did not cause endothelial dysfunction or have an effect on ABPM, providing further reassurance regarding the safety of dalcetrapib • dalcetrapib reduced CETP activity and increased HDL-C levels by 31% without affecting NO-dependent endothelial function • in contrast to torcetrapib, dalcetrapib did not raise blood pressure • This trial also demonstrates the feasibility of using FMD to test the influence of novel cardiovascular compounds on the biology of the vessel wall • Further testing in dal-OUTCOMES

  4. HDL – a noveltarget in coronarydisease ? HDL The “good“ cholesterol ?

  5. HDL: proposed anti-atherogeniceffects SR-BI? ABCG1 SR-BI LDL-R 1. HDL-mediatedpromotionof RCT (reversecholesteroltransport) VLDL/ LDL CE CETP TG A-I A-I FC PLTP CE FC LCAT Nascent HDL Mature HDL CE ABCA1 FC Bile HDL Macrophage Liver 2. Direct HDL-mediatedendothelial-protective potential anti-atherogeniceffects Anti-apoptotic Effects Endothelial Repair Endothelial NO Production Anti-inflammatory Effects Anti-thrombotic Effects Besler C et al. & Lüscher T, Landmesser U. CurrPharmacol Des 2010, 16: 1480-93

  6. Healthy P<0.025 sCAD 30 ACS 20 10 production Endothelial nitric oxide [in % of buffer-treated cells] 0 -10 -20 D g/ml 25 m 50 m g/ml 100 m g/ml HDL HDL HDL HDL –effects on endothelialcellnitricoxideproductionin patientswith CAD Besler C et al. & von Eckardstein, Lüscher T, Landmesser U. J ClinInvest2011;121(7):2693-708

  7. PL FC PL FC TG TG HDL metabolism – potential targets ? (1) apoA-I (lipid-free) (1) apoA-I (lipid-free) BA (2)ABCA1 ABCA1 FC CE Bile (5) SR-BI Nascent HDL LDLR TG-richlipoproteins (e.g. VLDL) (2) ABCA1 PLTP ABCG1 VLDL/LDL apoB Peripheraltissues(includinglipid-laden macrophages) (3) LCAT CE apoB CE (4) CETP Mature HDL Besler C, Lüscher T, Landmesser U. EMBO Mol Med 2011 (in press)

  8. HDL as a Therapeutic Target • Firm epidemiological link to CV outcome • Exciting therapeutic opportunity • HDL is complex particle with multiple functions • First CETP inhibitor Torcetrapib caused increased mortality • Current trials will define clinical role for HDL elevation

More Related